At a glance
- Originator Novartis
- Class Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 04 Dec 1998 No-Development-Reported for Epilepsy in United Kingdom (Unknown route)
- 13 Oct 1995 New profile
- 13 Oct 1995 Preclinical development for Epilepsy in United Kingdom (Unknown route)